The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma-Reference-Cited by-同舟云学术

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Published:2015-01-21 Issue:8 Volume:21 Page:1916-1924
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Pokorny Jenny L.,Calligaris David,Gupta Shiv K.,Iyekegbe Dennis O.,Mueller Dustin,Bakken Katrina K.,Carlson Brett L.,Schroeder Mark A.,Evans Debra L.,Lou Zhenkun,Decker Paul A.,Eckel-Passow Jeanette E.,Pucci Vincenzo,Ma Bennett,Shumway Stuart D.,Elmquist William F.,Agar Nathalie Y.R.,Sarkaria Jann N.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology;Neuro-Oncology;2024-03-22

2. A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate;Journal of Controlled Release;2023-12

3. Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing;Journal of Biomolecular Structure and Dynamics;2023-08-26

4. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling;Nature Medicine;2023-07-24

5. Targeting DNA damage response pathways in glioblastoma: From mechanistic insights to advances in the clinic;New Insights Into Glioblastoma;2023